Work

Osimertinib in previously EGFR-TKI treated non-small cell lung cancer (NSCLC) patients without T790M mutation: Real-world evidence.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.e21631

Authors: Yung-Hung Luo, Han Liu, Jason A. Wampfler, Henry D. Tazelaar, Yalun Li, Tobias Peikert, Dan Liu, Konstantinos Leventakos, Yuh-Min Chen, Yanan Yang, Shih-Hwa Chiou, Ping Yang

Institutions: Taipei Veterans General Hospital, First Hospital of Jilin University, Mayo Clinic, Mayo Clinic in Arizona, Sichuan University, West China Hospital of Sichuan University, National Yang Ming University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W3032043804

Cites:

Cited by:

Related to: 10